These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 33628202

  • 1. Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells.
    Webendörfer M, Reinhard L, Stahl RAK, Wiech T, Mittrücker HW, Harendza S, Hoxha E.
    Front Immunol; 2020; 11():586012. PubMed ID: 33628202
    [Abstract] [Full Text] [Related]

  • 2. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, Guigonis V, Ducret F, Presne C, Pirson Y, Hourmant M, Glachant JC, Vendrely B, Moranne O, Faguer S, Chauveau D.
    Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T, Masuda T, Saito S, Kato N, Ishimoto T, Kato S, Kosugi T, Tsuboi N, Kitamura H, Tsuzuki T, Ito Y, Maruyama S.
    Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
    [Abstract] [Full Text] [Related]

  • 4. Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
    Iwabuchi Y, Moriyama T, Itabashi M, Takei T, Nitta K.
    Contrib Nephrol; 2018 Feb; 195():12-19. PubMed ID: 29734146
    [Abstract] [Full Text] [Related]

  • 5. Minimal change disease with maximum immunosuppression: successful treatment of steroid-dependent minimal change disease with rituximab.
    Pinto H, Oliveira N, Costa F, Alves R.
    BMJ Case Rep; 2018 Feb 05; 2018():. PubMed ID: 29437743
    [Abstract] [Full Text] [Related]

  • 6. Rituximab in adult patients with immunosuppressive-dependent minimal change disease.
    Hoxha E, Stahl RA, Harendza S.
    Clin Nephrol; 2011 Aug 05; 76(2):151-8. PubMed ID: 21762648
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of rituximab in thymoma associated minimal change disease: case report.
    El Ouafi Z, Mugnier C, Jeannet R, Danthu C, Duval M, Belle Mbou V, Touré F.
    BMC Nephrol; 2021 Sep 07; 22(1):303. PubMed ID: 34493204
    [Abstract] [Full Text] [Related]

  • 8. Rituximab for minimal change disease in adults: long-term follow-up.
    Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M.
    Nephrol Dial Transplant; 2014 Apr 07; 29(4):851-6. PubMed ID: 24121763
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
    Taguchi S, Ohtake T, Mochida Y, Ishioka K, Moriya H, Hidaka S, Kobayashi S.
    Clin Exp Nephrol; 2020 Dec 07; 24(12):1132-1139. PubMed ID: 32761467
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of low-dose rituximab in minimal change disease and prevention of relapse.
    Zhang J, Zhao H, Li X, Qian R, Gao P, Lu S, Ma Z.
    BMC Nephrol; 2023 Apr 26; 24(1):112. PubMed ID: 37101300
    [Abstract] [Full Text] [Related]

  • 11. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.
    Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N.
    BMC Nephrol; 2020 Apr 15; 21(1):134. PubMed ID: 32293308
    [Abstract] [Full Text] [Related]

  • 12. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults.
    Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, Tsuruta Y, Ochi A, Amemiya N, Mochizuki T, Uchida K, Tsuchiya K, Nitta K.
    Nephrol Dial Transplant; 2013 May 15; 28(5):1225-32. PubMed ID: 23239834
    [Abstract] [Full Text] [Related]

  • 13. Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS.
    Osterholt T, Todorova P, Kühne L, Ehren R, Weber LT, Grundmann F, Benzing T, Brinkkötter PT, Völker LA.
    Sci Rep; 2023 Apr 28; 13(1):6980. PubMed ID: 37117201
    [Abstract] [Full Text] [Related]

  • 14. NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome.
    Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V, Sahali D.
    J Autoimmun; 2018 Mar 28; 88():91-102. PubMed ID: 29056249
    [Abstract] [Full Text] [Related]

  • 15. Rituximab and minimal change nephrotic syndrome: a therapeutic option.
    Takei T, Nitta K.
    Clin Exp Nephrol; 2011 Oct 28; 15(5):641-647. PubMed ID: 21611755
    [Abstract] [Full Text] [Related]

  • 16. Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome.
    Sawara Y, Itabashi M, Kojima C, Tabata H, Kamei D, Kawanishi K, Moriyama T, Sugiura H, Tsukada M, Takei T, Ogawa T, Yoshida T, Arai J, Uchida K, Tsuchiya K, Nitta K.
    Clin Nephrol; 2009 Jul 28; 72(1):69-72. PubMed ID: 19640390
    [Abstract] [Full Text] [Related]

  • 17. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network.
    Chen DP, Helmuth ME, Smith AR, Canetta PA, Ayoub I, Mucha K, Kallash M, Kopp JB, Gbadegesin R, Gillespie BW, Greenbaum LA, Parekh RS, Hunley TE, Sperati CJ, Selewski DT, Kidd J, Chishti A, Reidy K, Mottl AK, Gipson DS, Srivastava T, Twombley KE, CureGN Consortium.
    Am J Kidney Dis; 2023 Jun 28; 81(6):695-706.e1. PubMed ID: 36608921
    [Abstract] [Full Text] [Related]

  • 18. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P, Bonanni A, Ghiggeri GM.
    BMJ Open; 2017 Mar 17; 7(3):e013319. PubMed ID: 28314744
    [Abstract] [Full Text] [Related]

  • 19. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations.
    François H, Daugas E, Bensman A, Ronco P.
    Am J Kidney Dis; 2007 Jan 17; 49(1):158-61. PubMed ID: 17185157
    [Abstract] [Full Text] [Related]

  • 20. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM.
    Clin J Am Soc Nephrol; 2016 Apr 07; 11(4):710-20. PubMed ID: 26585985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.